Pharming Group NV (PHAR): Price and Financial Metrics
GET POWR RATINGS... FREE!
PHAR Stock Summary
- PHAR's went public 2.26 years ago, making it older than only 9.68% of listed US stocks we're tracking.
- With a price/earnings ratio of 66.72, PHARMING GROUP NV P/E ratio is greater than that of about 92.12% of stocks in our set with positive earnings.
- Price to trailing twelve month operating cash flow for PHAR is currently 42.39, higher than 89.75% of US stocks with positive operating cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to PHARMING GROUP NV are BKYI, TACT, CMCM, SCYX, and ISSC.
- To check out PHARMING GROUP NV's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001828316.
PHAR Stock Price Chart Interactive Chart >
PHAR Price/Volume Stats
| Current price | $13.50 | 52-week high | $17.81 |
| Prev. close | $12.95 | 52-week low | $6.10 |
| Day low | $12.75 | Volume | 14,200 |
| Day high | $13.75 | Avg. volume | 24,537 |
| 50-day MA | $12.64 | Dividend yield | N/A |
| 200-day MA | $10.93 | Market Cap | 886.07M |
Pharming Group NV (PHAR) Company Bio
Pharming Group NV is a biopharmaceutical company involved with the development, production and commercialization of human therapeutic proteins to be used in highly innovative therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage, and surgical/traumatic bleeding.
Latest PHAR News From Around the Web
Below are the latest news stories about PHARMING GROUP NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back and get ready for another day of trading with a breakdown of the biggest pre-market stock movers for Monday! |
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock UpPharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same. |
FDA Approves Pharming's Immune Disorder Drug, As First APDS TherapyThe FDA approved Pharming Group N.V.'s (NASDAQ: PHAR) Joenja (leniolisib) for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the U.S. for APDS, a rare and progressive primary immunodeficiency. The FDA evaluated the Joenja application for APDS under Priority Review. Joenja is expected to launch in the US in early April and will be av |
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDSPharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the US for APDS, a rare and progressive primary immunodeficiency. The FDA evaluated |
UPDATE 1-US FDA approves Pharming's immune disorder drugThe U.S. Food and Drug Administration (FDA) on Friday approved Dutch firm Pharming Group's drug to treat a rare genetic disorder that leads to a weakened immune system, the company said. Leniolisib, to be sold under the brand name Joenja, becomes the first approved drug to treat activated phosphoinositide 3-kinase delta syndrome (APDS), a primary immunodeficiency that affects about 1 to 2 people in a million. Joenja is expected to launch in the U.S. in early April and will be available for shipment in mid-April, Pharming said. |
PHAR Price Returns
| 1-mo | 12.40% |
| 3-mo | 22.39% |
| 6-mo | 37.20% |
| 1-year | 50.17% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 22.39% |
| 2022 | 23.38% |
| 2021 | -41.16% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...